Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1993;21:654-659

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Antonipillai, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Antonipillai, I.

Hypertension, Vol 21, 654-659, Copyright © 1993 by American Heart Association


ARTICLES

Epidermal growth factor is a potent inhibitor of renin secretion

I Antonipillai
USC Medical Center, Division of Endocrinology, Los Angeles 90033.

Epidermal growth factor (EGF) is not only a cell mitogen but a potent vasoconstrictor that shares many properties with angiotensin II. Because EGF is localized in the kidney, we have studied the direct effects of EGF on renin secretion using both static incubations and perifusions of rat renal cortical slices. EGF at 5 x 10(-9) M significantly inhibited renin secretion in static incubations (control, 100 +/- 3%; EGF, 72 +/- 3%; p < 0.001). When added to perifusions, EGF acted rapidly, reducing renin secretion at the earliest time period (10 minutes). Similarly, transforming growth factor-alpha, which can bind to the EGF receptor, also inhibited renin secretion (control, 92 +/- 8%; transforming growth factor-alpha [2 x 10(-9) M], 63 +/- 4%; p < 0.02). Because both prostaglandins and lipoxygenase products of arachidonic acid have been shown to play a role in some EGF-mediated actions, we examined these possible mechanisms of EGF action. Meclofenamate, a cyclooxygenase blocker, and BW755c and baicalein, both lipoxygenase blockers, were studied. None of these agents altered EGF- mediated renin inhibition. EGF action has also been coupled to the stimulation of tyrosine kinase activity; therefore, we examined the effects of the tyrosine kinase inhibitors genistein and quercetin. Both genistein (10(-5) M) and quercetin (10(-5) M) abolished the inhibition of renin by EGF (control, 100 +/- 3%; EGF, 82 +/- 4%; EGF plus genistein, 110 +/- 7%; p < 0.01; EGF, 75 +/- 4%; EGF plus quercetin, 92 +/- 4%; p < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)